Ryan CW - Search Results

1

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.

Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M. Alumkal JJ, et al. Among authors: ryan cw. Invest New Drugs. 2015 Apr;33(2):480-9. doi: 10.1007/s10637-014-0189-z. Epub 2014 Nov 29. Invest New Drugs. 2015. PMID: 25431127 Free PMC article. Clinical Trial.

2

CI-980 in advanced melanoma and hormone refractory prostate cancer.

Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ. Ryan CW, et al. Invest New Drugs. 2000 May;18(2):187-91. doi: 10.1023/a:1006382014403. Invest New Drugs. 2000. PMID: 10857996 Clinical Trial.

3

Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.

Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM. Bland LB, et al. Among authors: ryan cw. Cancer. 2005 Feb 15;103(4):717-23. doi: 10.1002/cncr.20857. Cancer. 2005. PMID: 15641029 Free article. Clinical Trial.

4

High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.

Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. Tiffany NM, et al. Among authors: ryan cw. J Urol. 2005 Sep;174(3):888-92. doi: 10.1097/01.ju.0000169261.42298.e6. J Urol. 2005. PMID: 16093981 Clinical Trial.

5

Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer.

Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, Beer TM. Purnell JQ, et al. Among authors: ryan cw. J Lipid Res. 2006 Feb;47(2):349-55. doi: 10.1194/jlr.M500276-JLR200. Epub 2005 Nov 20. J Lipid Res. 2006. PMID: 16299398 Free article.

6

Testosterone loss and estradiol administration modify memory in men.

Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS. Beer TM, et al. Among authors: ryan cw. J Urol. 2006 Jan;175(1):130-5. doi: 10.1016/S0022-5347(05)00049-2. J Urol. 2006. PMID: 16406889

7

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Ryan CW, et al. J Urol. 2006 Sep;176(3):972-8; discussion 978. doi: 10.1016/j.juro.2006.04.078. J Urol. 2006. PMID: 16890673 Clinical Trial.

8

High dose calcitriol may reduce thrombosis in cancer patients.

Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. Beer TM, et al. Among authors: ryan cw. Br J Haematol. 2006 Nov;135(3):392-4. doi: 10.1111/j.1365-2141.2006.06322.x. Epub 2006 Sep 19. Br J Haematol. 2006. PMID: 16984385 Free article. Clinical Trial.

9

Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.

Beer TM, Ryan C, Bhat G, Garnick M; Abarelix Study Group. Beer TM, et al. Anticancer Drugs. 2006 Oct;17(9):1075-9. doi: 10.1097/01.cad.0000231476.84782.55. Anticancer Drugs. 2006. PMID: 17001181 Clinical Trial.

10

Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.

Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Beer TM, et al. Among authors: ryan cw. Cancer Chemother Pharmacol. 2007 Apr;59(5):581-7. doi: 10.1007/s00280-006-0299-1. Epub 2006 Oct 26. Cancer Chemother Pharmacol. 2007. PMID: 17066293 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page